Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo?¶
Notebook ID: nb-SDA-2026-04-25-gapdebate-18cce7b525 · Analysis: SDA-2026-04-25-gapdebate-18cce7b525
Domain: neurodegeneration · Date: 2026-04-24
Research Question¶
The debate highlighted that most SCFA studies use pharmacological doses (mM) rather than physiologically achievable concentrations. This dose-response gap is critical for translational potential and determines whether dietary/probiotic interventions could be therapeutically meaningful.
Source: Debate session sess_SDA-2026-04-16-gap-20260416-121711_20260416-134918 (Analysis: SDA-2026-04-16-gap-20260416-121711)
Debate Summary¶
Debate transcript not available for this analysis.
Hypotheses Ranked by Composite Score¶
Total hypotheses: 6
| Title | Composite | Confidence | Novelty | Feasibility | Impact |
|---|---|---|---|---|---|
| Physiological SCFAs may confer indirect anti-synuclein benefit through an entero | 0.67 | 0.6 | 0.62 | 0.72 | 0.69 |
| Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-fi | 0.65 | 0.63 | 0.66 | 0.74 | 0.67 |
| The most realistic translational use of physiological SCFAs is as an adjunct to | 0.61 | 0.49 | 0.68 | 0.66 | 0.71 |
| Direct neuronal HDAC inhibition is unlikely to mediate therapeutic alpha-synucle | 0.56 | 0.71 | 0.39 | 0.84 | 0.18 |
| Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLR | 0.55 | 0.67 | 0.64 | 0.76 | 0.31 |
| Propionate may outperform acetate or butyrate at physiological exposure, but mai | 0.44 | 0.32 | 0.58 | 0.55 | 0.34 |
Knowledge Graph Edges¶
No KG edges found for this analysis.
Key Citations¶
No citations found for this analysis.